A recent nationwide real-world data (RWD) study, published in European Journal of Gastroenterology & Hepatology, demonstrated that ustekinumab provides sustained effectiveness in treating moderate to severe ulcerative colitis (UC). Conducted as a chart review study, the study included nearly all patients in Finland who received ustekinumab between September 2019 and December 2021. Data collection was performed using a data collection system inside SPESiOR secure processing environment.
- Key findings of the study include:
- Partial Mayo Score and faecal calprotectin values significantly decreased from median 5.0/1262 at baseline to 1.0/215 after one year.
- Ustekinumab persistency was 63% at one year.
- Faecal calprotectin and extraintestinal manifestations were found to be associated with ustekinumab persistency.
- Discontinuation was most commonly due to primary nonresponse (65 patients, 75% of reasons).
- Antibodies to ustekinumab were uncommon (<5 patients, <21%), and discontinuation due to adverse effects were rare (<5 patients, <6%).
The study’s findings align with previous real-world evidence and offer valuable insights into the long-term effectiveness of ustekinumab in real life routine clinical practice.
Read the article here.
Contact Erkki Soini (CEO) for more information.